Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dulanermin

Drug Profile

Dulanermin

Alternative Names: AMG-951; PRO 1762; Recombinant human Apo2L/TRAIL; RG 3639; Rh-Apo2L - Amgen/Genentech; rhApo2L/TRAIL; TNF-related apoptosis-inducing ligand; TRAIL/Apo2L

Latest Information Update: 21 Jun 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 26 Jul 2011 Discontinued - Phase-I for Colorectal cancer in USA (IV)
  • 15 Jun 2011 Genentech and Amgen terminate a phase I/II trial in Non-Hodgkin's lymphoma in Australia, European Union, New Zealand and USA(NCT00400764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top